These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11688965)

  • 81. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors.
    Palmer D; Tsoi K; Maurice DH
    Circ Res; 1998 May; 82(8):852-61. PubMed ID: 9576105
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.
    Cherry JA; Thompson BE; Pho V
    Biochim Biophys Acta; 2001 Mar; 1518(1-2):27-35. PubMed ID: 11267656
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis.
    Osinski MT; Schrör K
    Biochem Pharmacol; 2000 Aug; 60(3):381-7. PubMed ID: 10856433
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux.
    Lin G; Bornfeldt KE
    Biochem Biophys Res Commun; 2002 Jan; 290(2):663-9. PubMed ID: 11785950
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects.
    Landells LJ; Spina D; Souness JE; O'Connor BJ; Page CP
    Pulm Pharmacol Ther; 2000; 13(5):231-9. PubMed ID: 11003567
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.
    Silva PM; Alves AC; Serra MF; Pires AL; Silva JP; Barreto EO; Cordeiro RS; Jose PJ; Teixeira MM; Lagente V; Martins MA
    Br J Pharmacol; 2001 Sep; 134(2):283-94. PubMed ID: 11564646
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Role of phosphodiesterase 4 isoenzyme in alkaline phosphatase activation by calcitonin in porcine kidney LLC-PK1 cells.
    Miyamoto K; Suzuki R; Horita T; Yamamoto S; Waki Y; Takagi K
    Jpn J Pharmacol; 1998 Feb; 76(2):193-8. PubMed ID: 9541282
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Changes in phosphodiesterase activity in the developing rat submandibular gland.
    Tanaka S; Shimooka S; Shimomura H
    Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.
    MacKenzie SJ; Houslay MD
    Biochem J; 2000 Apr; 347(Pt 2):571-8. PubMed ID: 10749688
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
    Nam G; Yoon CM; Kim E; Rhee CK; Kim JH; Shin JH; Kim SH
    Bioorg Med Chem Lett; 2001 Mar; 11(5):611-4. PubMed ID: 11266153
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells.
    Ogawa R; Streiff MB; Bugayenko A; Kato GJ
    Blood; 2002 May; 99(9):3390-7. PubMed ID: 11964308
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.
    Nadur NF; de Azevedo LL; Caruso L; Graebin CS; Lacerda RB; Kümmerle AE
    Eur J Med Chem; 2021 Feb; 212():113123. PubMed ID: 33412421
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Development of a fission yeast-based high-throughput screen to identify chemical regulators of cAMP phosphodiesterases.
    Ivey FD; Wang L; Demirbas D; Allain C; Hoffman CS
    J Biomol Screen; 2008 Jan; 13(1):62-71. PubMed ID: 18227226
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Phosphodiesterase 4D and heart failure: a cautionary tale.
    Lehnart SE; Marks AR
    Expert Opin Ther Targets; 2006 Oct; 10(5):677-88. PubMed ID: 16981825
    [TBL] [Abstract][Full Text] [Related]  

  • 95. PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER.
    Vang AG; Ben-Sasson SZ; Dong H; Kream B; DeNinno MP; Claffey MM; Housley W; Clark RB; Epstein PM; Brocke S
    PLoS One; 2010 Aug; 5(8):e12011. PubMed ID: 20711499
    [TBL] [Abstract][Full Text] [Related]  

  • 96. ABCD of the phosphodiesterase family: interaction and differential activity in COPD.
    Halpin DM
    Int J Chron Obstruct Pulmon Dis; 2008; 3(4):543-61. PubMed ID: 19281073
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.
    Sun J; Xiao Z; Haider A; Gebhard C; Xu H; Luo HB; Zhang HT; Josephson L; Wang L; Liang SH
    J Med Chem; 2021 Jun; 64(11):7083-7109. PubMed ID: 34042442
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A dual and conflicting role for imiquimod in inflammation: A TLR7 agonist and a cAMP phosphodiesterase inhibitor.
    Ernst O; Failayev H; Athamna M; He H; Tsfadia Y; Zor T
    Biochem Pharmacol; 2020 Dec; 182():114206. PubMed ID: 32828805
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Renal cell proliferation and the two faces of cyclic adenosine monophosphate.
    Grantham JJ
    J Lab Clin Med; 1997 Nov; 130(5):459-60. PubMed ID: 9390632
    [No Abstract]   [Full Text] [Related]  

  • 100. Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility.
    Murata K; Kameyama M; Fukui F; Ohigashi H; Hiratsuka M; Sasaki Y; Kabuto T; Mukai M; Mammoto T; Akedo H; Ishikawa O; Imaoka S
    Clin Exp Metastasis; 1999; 17(6):525-30. PubMed ID: 10763919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.